(Reuters) – Inovio Pharmaceuticals said on Monday it plans to start a global late-stage trial for its COVID-19 vaccine candidate, INO-4800, this summer. (https://refini.tv/3uAVRFV)
The drug developer earlier in the day reported promising results from a mid-stage trial of its vaccine candidate.
(Reporting by Trisha Roy in Bengaluru; Editing by Shailesh Kuber)
